Spectradyne’s innovative analytical nanotechnology accelerates drug development by enabling safety-critical particle testing in minutes instead of weeks.
Spectradyne was formed in late 2013 to commercialize nanoparticle analysis technology invented at UC Santa Barbara. The company has received almost $3 million in SBIR funding from the NSF and NIH and has sold or rented more than 20 instruments. The company also manufactures and sells the disposable microfluidic cartridges required to make measurements. Spectradyne is fundraising to increase sales and marketing efforts and to expand production.